Altered Viral Fitness of HIV-1 Following Failure of Protease Inhibitor-Based Therapy
- 1 December 2000
- journal article
- clinical trial
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 25 (4) , 289-295
- https://doi.org/10.1097/00042560-200012010-00001
Abstract
HIV-1 isolated from patients with improved CD4+ T-cell counts despite virologic failure on a nucleoside reverse transcriptase inhibitor (NRTI) and protease inhibitor (PI)-containing regimen were characterized. Five paired virus isolates from patients before and after zidovudine, lamivudine, and ritonavir treatment were tested. Human peripheral blood leukocyte-reconstituted severe combined immunodeficient (hu-PBL-SCID) mice were infected with pre-or posttreatment isolates and plasma HIV-1 RNA levels and CD4+ T cells were measured. Two of five post-treatment isolates exhibited decreased replication in hu-PBL-SCID mice compared with the paired pretreatment isolate, and both had the V82A mutation in protease associated with resistance to PI. One additional posttreatment isolate with the M184V mutation in reverse transcriptase showed diminished replication. CD4+ T-cell depletion was similar following infection with either the pre-or posttreatment isolates. Subtle losses in the replication capacity of PI-or NRTI-resistant viruses may contribute to relative preservation of CD4+ T-cell counts in persons who experience virologic failure. Cytopathic effects of viral infection for target T cells vary from patient to patient but appear not to be influenced by mutations associated with failure of therapy in this system.Keywords
This publication has 13 references indexed in Scilit:
- Sustained CD4+T Cell Response after Virologic Failure of Protease Inhibitor–Based Regimens in Patients with Human Immunodeficiency Virus InfectionThe Journal of Infectious Diseases, 2000
- Effect of Zidovudine Resistance Mutations on Virologic Response to Treatment with Zidovudine‐Lamivudine‐Ritonavir: Genotypic Analysis of Human Immunodeficiency Virus Type 1 Isolates from AIDS Clinical Trials Group Protocol 315The Journal of Infectious Diseases, 2000
- Dynamic correlation of apoptosis and immune activation during treatment of HIV infectionCell Death & Differentiation, 1999
- Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimenAIDS, 1999
- Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence DatabaseNucleic Acids Research, 1999
- Immunologic Responses Associated with 12 Weeks of Combination Antiretroviral Therapy Consisting of Zidovudine, Lamivudine, and Ritonavir: Results of AIDS Clinical Trials Group Protocol 315The Journal of Infectious Diseases, 1998
- Improvement in CD4+ Cell Counts despite Persistently Detectable HIV LoadNew England Journal of Medicine, 1998
- CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART)The Lancet, 1998
- Extensive polymorphisms observed in HIV–1 clade B protease gene using high–density oligonucleotide arraysNature Medicine, 1996
- Human Immunodeficiency Virus Infection of Human Cells Transplanted to Severe Combined Immunodeficient MicePublished by Elsevier ,1996